4,720 reports of this reaction
2.0% of all CETIIRIZINE reports
#4 most reported adverse reaction
RASH is the #4 most commonly reported adverse reaction for CETIIRIZINE, manufactured by Amneal Pharmaceuticals LLC. There are 4,720 FDA adverse event reports linking CETIIRIZINE to RASH. This represents approximately 2.0% of all 233,494 adverse event reports for this drug.
Patients taking CETIIRIZINE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for CETIIRIZINE, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for CETIIRIZINE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 4,720 FDA reports for CETIIRIZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.0% of all adverse event reports for CETIIRIZINE, making it a notable side effect.
If you experience rash while taking CETIIRIZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.